Compare DexCom, Inc. (DXCM) vs Rockwell Automation (ROK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Rockwell Automation — how do they compare? DexCom, Inc. trades at $84.38 (market cap $31.86B), while Rockwell Automation trades at $436.4 (market cap $48.21B). The key difference: Rockwell Automation is the larger of the two by market cap, and Rockwell Automation pays a 1.27% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Rockwell Automation for 74 Days on average.
| DXCM | ROK | |
|---|---|---|
Market Cap | $31.86B | $48.21B |
Volume | 3,607,070 | 953,342 |
Sector | Health | Industrials |
52-Week High | $92.34 | $495.08 |
52-Week Low | $54.84 | $333.75 |
Typical Hold Time | 62 Days | 74 Days |
Enterprise Value | $31.32B | $51.34B |
Dividend Yield | — | 1.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $84.3, up 1.09% today, with a bearish technical signal despite strong fundamentals. The company reported Q2 2026 EPS of $0.70, beating estimates, continuing a trend of earnings outperformance. Revenue growth is robust, with 2025 revenue reaching $4.66 billion and net income margin improving to 20.12%. Analyst consensus is strongly bullish with an 80.77% buy rating and a $95.07 price target, suggesting significant upside from current levels.
The outlook for DXCM is positive driven by expansion in continuous glucose monitoring for Type 2 diabetes, as highlighted in recent company reports. Key risks include competitive pressures and reimbursement challenges. With solid cash flow generation and institutional support, the stock presents a growth opportunity, though investors should monitor execution against high expectations.
Rockwell Automation (ROK) trades at $441.9, down 1.96% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $489.89 implying 11% upside. The company has beaten EPS estimates for three consecutive quarters, with Q3 2026 results pending, and maintains strong profitability with a 13.38% net income margin and 34.47% ROE. Recent news highlights leadership in industrial automation, including partnerships in AI cybersecurity and robotic platforms.
ROK presents a growth opportunity driven by automation demand and digital transformation trends, but faces risks from high valuation multiples (P/E 41.38) and cyclical industrial spending. Analyst sentiment is mixed with 68% hold ratings, reflecting caution amid solid fundamentals. Investors should weigh earnings consistency against premium pricing.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Rockwell Automation
Rockwell Automation is a pure-play automation competitor that is the successor entity to Rockwell International, which spun off its former Rockwell Collins avionics segment in 2001. As of fiscal 2021, the firm operates through three segments--intelligent devices, software and control, and lifecycle services. Intelligent devices contains its drives, sensors, and industrial components, software and control contains its information and network and security software, while lifecycle services contains its consulting and maintenance services as well as its Sensia JV with Schlumberger.
Read more on ROK →
